Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

45.49 -0.57 (-1.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 660,113
Open 46.61
Bid (Size) 45.10 (1)
Ask (Size) 45.80 (1)
Prev. Close 46.06
Today's Range 45.47 - 46.95
52wk Range 38.94 - 72.00
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Cathie Wood Stocks to Buy Hand Over Fist Right Now
These two high-tech stocks could dramatically outperform the broader market in the years ahead. 
Via The Motley Fool
$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years
I favor holding onto these players for the long term to truly benefit from their earnings potential. 
Via The Motley Fool

Performance

YTD
+10.95%
+10.95%
1 Month
-8.45%
-8.45%
3 Month
-19.10%
-19.10%
6 Month
+2.57%
+2.57%
1 Year
-25.55%
-25.55%

More News

Read More
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
Via The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Where Will CRISPR Therapeutics Be in 5 Years?
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
Via The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Via The Motley Fool
2 Top Trends to Invest $500 In Right Now
Via The Motley Fool
Looking for Growth? These Companies' Revenue May Skyrocket
Via The Motley Fool
If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today
Via The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
Via The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
3 Top Healthcare Stocks Defying the Bear Market
Via The Motley Fool
Better Bull Market Buy: CRISPR vs. Medtronic Stock
Via The Motley Fool
3 Biotech Blockbusters to Turn $5,000 Into $50,000
Via InvestorPlace
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
Via The Motley Fool
CRSP Stock Alert: What to Know as CRISPR Therapeutics Co-Founder Steps Down
Via InvestorPlace
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street
Via The Motley Fool
With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock?
Via The Motley Fool
The 3 Best Biotech Stocks to Buy Now: September 2023
Via InvestorPlace
2 Spectacular Growth Stocks You Can Buy in September With No Hesitation
Via The Motley Fool
3 Beaten-Down Biotech Stocks Bound for a Bounce Back
Via InvestorPlace
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
Via The Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now
Via The Motley Fool
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.